Download full text PDF

L.V. Bel'skaya Ph.D. (Chem.), Associate Professor, Omsk State Technical University; JSC «ChemService» (Moscow) E-mail: V.K. Kosenok Dr.Sc. (Med.), JSC «ChemService» (Moscow); Omsk State Medical University Zh. Massard Professor, University Hospital of Strasbourg; Chief Oncologist of the University of Strasbourg E.E. Orlova Doctor of Clinical Laboratory Diagnostics, Head of the Immunological Laboratory, Clinical Oncology Dispensary (Omsk)

The optimization of methods of diagnosis and prediction of lung cancer, which occupies a leading position in the structure of oncologi-cal diseases, remains a relevant task up to date. Study objective: to study the level of cytokines and acute-phase proteins in saliva of patients with lung cancer. A case-control study was attended by 121 volunteers, who were divided into 3 groups: primary (diagnosed with lung cancer, n = 70), comparison (with non-malignant lung pathologies, n = 12) and control group (relatively healthy, n = 39). All participants answered the questionnaire, undergone biochemical study of saliva and histological verification of the diagnosis. Cross-group differences were evaluated using the non-parametric criterion. It has been shown that cytokine levels in the saliva of lung can-cer patients and healthy individuals do not differ statistically. The content of IL-2 and IL-4 in saliva reduces in case of both lung cancer and inflammatory lung diseases, whereas the levels of IL-18, IL-8 and TNF-α decrease in lung cancer and grow in non-tumorous pa-thologies. The progression of the tumor causes an increase in the level of proinflammatory cytokines (IL-6, IL-8, IL-18, TNF-α), whereas the levels of IL-2, IL-4 and IL-10 decrease. An increase in the level of C-reactive protein and tumor markers in the dynamics of lung cancer has been noted, but no significant differences from inflammatory lung diseases have been revealed. With different his-tological types of lung cancer, the nature of the changes in the parameters under study is ambiguous: differentiated between neuro-endocrine and non-small cell lung cancer, IL-2 and C-reactive protein, whereas IL-10 and CEA levels can distinguish squamous cell carcinoma from other histological types.

C-reactive protein
lung cancer

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Brailo V., Vucicevic-Boras V., Lukac J., Biocina-Lukenda D., Zilic-Alajbeg I., Milenovic A., Balija M. Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer // Med. Oral Patol. Oral Cir. Bucal. 2012. № 17. R. e10–e15.
  2. Byrne M.L., O’Brien-Simpson N.M., Reynolds E.C., Walsh K.A., Laughton K., Waloszek J.M., Woods M.J., Trinder J., Allen N.B. Acute phase protein and cytokine levels in serum and saliva: A comparison of detectable levels and correlations in a depressed and healthy adolescent sample // Brain, Behavior, and Immunity. 2013. № 34. R. 164−175.
  3. Gilbertson-White S., Aouizerat B.E., Miaskowski C. Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms // Biol. Res. Nurs. 2011. № 13. R. 15–24.
  4. Khan A. Detection and quantitation of forty-eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine // Journal of Proteomics. 2012. № 75. R. 4802−4819.
  5. Fernandez-Botran R., Miller J.J., Burns V.E., Newton T.L. Correlations among inflammatory markers in plasma, saliva and oral mucosal transudate in postmenopausal women with past intimate partner violence // Brain Behav. Immun. 2011. № 25. R. 314–321.
  6. Williamson S., Munro C., Pickler R., Grap M.J., Elswick R.K. Comparison of biomarkers in blood and saliva in healthy adults // Nurs. Res. Pract. 2012. Article ID 246178. 4 p.
  7. Cullen T., Thomas A.W., Webb R., Hughes M.G. The relationship between interleukin-6 in saliva, venous and capillary plasma, at rest and in response to exercise // Cytokine. 2015. V. 71, № 2. R. 397−400.
  8. Ouellet-Morin I., Danese A., Williams B., Arseneault L. Validation of a high-sensitivity assay for C-reactive protein in human saliva // Brain Behav. Immun. 2011. № 25. R. 640–646.
  9. Mirzaii-Dizgah I., Riahi E., Miri R. Serum and saliva levels of high-sensitivity C-reactive protein in acute myocardial infarction // J. Mol. Biomark. Diagn. 2:128. doi: 10.4172/2155-9929.1000128
  10. Pfaffe T., Cooper-White J., Beyerlein P., Kostner K., Punyadeera C. Diagnostic potential of saliva. Current state and future applications // Clin. Chem. 2011. № 57. R. 675–687.
  11. Javaid M.A., Ahmed A.S., Durand R., Tran S.D. Saliva as a diagnostic tool for oral and systemic diseases // Journal of oral biology and craniofacial research. 2016. V. 6. № 1. R. 67−76.
  12. Suzuki T., Omata K., Satoh T., Miyasaka T., Arai C., Maeda M., Matsuno T., Miyamura T. Quantitative detection of hepatitis C virus (HCV) RNA in saliva and gingival crevicular fluid of HCV-infected patients // J. Clin. Microbiol. 2005. № 43. R. 4413–4417.
  13. Shipper R.G., Silletti E., Vingerhoeds M.H. Saliva as research material: Biochemical, physicochemical and practical aspects // Archives of oral biology. 2007. № 52. R. 1114−1135.
  14. Papacosta E., Nassis G.P. Saliva as a tool for monitoring steroid, peptide and immune markers in sport and exercise science // Journal of Science and Medicine in Sport. 2011. № 14. R. 424–434.
  15. Granger D.A., Kivlighan K.T., Fortunato C., Harmon A.G., Hibel L.C., Schwartz E.B., Whembolua G.-L. Integration of salivary biomarkers into developmental and behaviorallyoriented research: problems and solutions for collecting specimens // Physiol. Behav. 2007. № 92. R. 583–590.
  16. Isaza-Guzmán D.M., Cardona-Vélez N., Gaviria-Correa D.E., Martínez-Pabón M.C., Castano-Granada M.C., Tabón-Arroyave S.I. Association study between salivary levels of interferon (IFN)-gamma, interleukin (IL)-17, IL-21, and IL-22 with chronic periodontitis // Archives of Oral Biology. 2015. № 60. R. 91−99.
  17. Dafar A., Rico P., Işik A., Jontell M., Cevik-Aras H. Quantitative detection of epidermal growth factor and interleukin-8 in whole saliva of healthy individuals // Journal of Immunological Methods. 2014. № 408. R. 46−51.
  18. Alejnikov A.S., Gajduk I.V., Panin A.M., Babkina I.V., Kushlinskij N.E. Provospalitel'nye tsitokiny v sljunnom sekrete bol'nyh hronicheskim sialodohitom // Vestnik TGU. 2014. T. 19. № 6. R. 1909−1914.
  19. Rhodus N.L., Ho V., Miller C.S., Myers S., Ondrey F. NF-kB dependent cytokine levels in saliva of patients with oral preneoplastics lesions and oral squamous cell carcinoma // Cancer Detection and Prevention. 2005. № 29. R. 42−45.
  20. Schapher M., Wendler O., Gröschl M. Salivary cytokines in cell proliferation and cancer // Clinica Chimica Acta. 2011. № 412. R. 1740−1748.
  21. Jacobs R., Tshehla E., Malherbe S., Kriel M., Loxton A.G., Stanley K., van der Spuy G., Walzl G., Chegou N.N. Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment // Cytokine. 2016. № 81. R. 50−56.
  22. . Yano T., Yoshino I., Yokoyama H., Fukuyama Y., Takai E., Asoh H., Ichinose Y. The clinical significance of serum soluble interleukin-2 receptors in lung cancer // Lung Cancer.
  23. 1996. № 15. R. 79−84.
  24. Chi X., Tai H.-H. Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells // Experimental Cell Research. 2010. № 316. R. 2251−2259.
  25. Ryan B.M., Pine S.R., Chaturvedi A.K., Caporaso N., Harris C.C. A Combined Prognostic Serum Interleukin-8 and Interleukin- 6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial // Journal of Thoracic Oncology. 2014. V. 9. № 10. R. 1494−1503.
  26. Luppi F., Longo A.M., de Boer W.I., Rabe K.F., Hiemstra P.S. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation // Lung Cancer. 2007. № 56. R. 25−33.
  27. Rovina N., Hillas G., Dima E., Vlastos F., Loukides S., Veldekis D., Roussos C., Alhanatis M., Bakakos P. VEGF and IL-18 in induced sputum of lung cancer patients // Cytokine. 2011. № 54. R. 277−281.
  28. O’Dowd C., McRae L.A., McMillan D.C., Kirk A., Milroy R. Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer // Journal of Thoracic Oncology. 2010; V. 5. № 7. R. 988−992.
  29. Pujol J.-L., Boher J.-M., Grenier J., Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients // Lung Cancer. 2001. V. 31. № 221–231.
  30. Okamura K., Takayama K., Izumi M., Harada T., Furuyama K., Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer // Lung Cancer. 2013. № 80. R. 45–49.
  31. Hoseok I., Cho J.-Y. Lung Cancer Biomarkers // Advances in Clinical Chemistry. 2015. № 72. R. 107−170.
  32. Scheglova M.Ju. Sistema tsitokinov v norme i pri boleznjah organov dyhanija // Bjulleten' fiziologii i patologii dyhanija. 2005. № 21. C. 93−97.
  33. Akdis M., Aab A., Altunbulakli C., Azkur K., Costa R.A., Crameri R., et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor b, and TNF-a: Receptors, functions, and roles in diseases // Journal of Allergy and Clinical Immunology. 2016. V. 138. № 4. R. 984−1010.
  34. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions // Annu. Rev. Immunol. 1999. № 17. R. 701–738.
  35. Ho L-J., Luo S-F., Lai J-H. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers // Biochemical Pharmacology. 2015. V. 97. № 1. R. 16−26.
  36. Seike M., Yanaihara N., Bowman E.D., et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier // J Natl. Cancer Inst. 2007. № 99. R. 1257–1269.
  37. Yatsunami J., Tsuruta N., Ogata K., Wakamatsu K., Takayama K., Kawasaki M., Nakanishi Y., Hara N., Hayashi S. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung // Cancer Letters. 1997. № 120. R. 101–108.
  38. Pine S.R., Mechanic L.E., Enewold L., et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer // J Natl Cancer Inst. 2011. № 103. R. 1112–1122.
  39. Erzutova M.V., Uspenskaja I.D., Majanskaja I.V., Korkotashvili L.V., Potehin P.P. Znachenie provospalitel'nyh tsitokinov v sekrete rotovoj polosti u bol'nyh tseliakiej // Meditsinskaja al'manah. 2011. T. 6. № 19. R. 179−182.
  40. Ushakova N.D., Nerodo G.A., Goroshinskaja I.A., Zlatnik E.Ju., Mkrtchjan E.T., Men'shenina A.P. Otsenka effektivnosti plazmafereza v lechenii bol'nyh rakom jaichnikov // Rossijskij meditsinskij zhurnal. 2014. № 3. S. 21−26.
  41. Chaturvedi A.K., Caporaso N.E., Katki H.A., et al. C-reactive protein and risk of lung cancer // J. Clin. Oncol. 2010. № 28. R. 2719–2726.
  42. Tozzoli R., Basso S.M.M., D’Aurizio F., Metus P., Lumachi F. Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review // Clinical Biochemistry. 2016. V. 49. № 16-17. R. 1227−1231.
  43. Kischkel S., Miekisch W., Sawacki A., Straker E.M., Trefz P., Amann A., Schubert J.K. Breath biomarkers for lung cancer detection and assessment of smoking related effects − confounding variables, influence of normalization and statistical algorithms // Clinica Chimica Acta. 2010. № 411. R. 1637−1644.
  44. Barlesi F., Gimenez C., Torre J.-P., Doddoli C., Mancini J., Greillier L., Roux F., Kleisbauer J.-P. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer // Respiratory Medicine. 2004. № 98. R. 357–362.
  45. Grunnet M., Sorensen J.B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer // Lung Cancer. 2012. № 76. R. 138–143.